(Information sent by the signatory company)
EJBY, Denmark, April 2, 2024 /PRNewswire/ -- Today Scantox, together with its majority owner Impilo, completed the acquisition of QPS Neuropharmacology, a leading drug discovery CRO specializing in neurodegenerative, rare diseases and mental disorders. The company, now integrated into the Scantox Group as Scantox Neuro, is recognized for its high-quality services that are deeply scientifically rooted and has an undisputed track record of serving a broad and loyal customer base around the world. With the acquisition of QPS Neuropharmacology, Scantox's value chain coverage is significantly expanded with unique and market-leading central nervous system (CNS) research capabilities.
Founded in 1999, the former QPS Neuropharmacology has a long history of developing expertise in lead optimization services and efficacy studies. The company has a 2,700 square meter state-of-the-art facility in Grambach, Austria, and employs more than 80 people. With in situ availability of validated transgenic and non-transgenic in vitro and in vivo models, the company addresses multiple targets within the growing area of the CNS and represents a unique partner for biotechnology and pharmaceutical companies in their drug development process.
"Since announcing the planned acquisition of QPS Neuropharmacology in November, we have worked extensively to prepare for the expansion of our business. This is a transformative addition to our Discovery division, significantly changing our lead optimization platform and expanding the depth and breadth of our services in the field of CNS and rare diseases. Scantox's rapid growth continues, providing our customers around the world with a continually improved level of service and scientific excellence," said Jeanet Løgsted, CEO of Scantox Group.
Manuela Prokesch, Director of Scantox Neuro GmbH, continued: "Becoming part of the Scantox Group will open up unique possibilities for us to offer an even larger portfolio of services to our clients. As an organisation, we look forward to integrating into a highly reliable company and reputable European CRO. , where we can take advantage of synergies and continue the growth journey together.
Under the new Neuro entity, Scantox Group will have more than 300 employees across six sites offering lead optimization, regulatory toxicology and CMC/analytical services.
Nicholas Hooge, Partner at Impilo, concluded: "Having closed this acquisition allows Scantox to significantly expand its service offering and customer reach. We are delighted to welcome the Austrian team to the Scantox group and see significant growth opportunities for the business. combined in the future.
Logo - https://mma.prnewswire.com/media/2288707...
View original content: https://www.prnewswire.com/news-releases/scantox-cierra-la-adquisicion-de-qps-neuropharmacology-ahora-scantox-neuro-302098290.html
